StethoMe has raised $5.0M in total across 2 funding rounds.
StethoMe's investors include TDJ Pitango Ventures.
StethoMe is a health technology company that develops an AI-powered smart stethoscope designed for home use. Its flagship product enables precise, real-time monitoring and detection of abnormal lung and heart sounds, providing immediate feedback on whether a medical consultation is necessary. The device serves patients, particularly children and individuals with respiratory conditions, by empowering them to monitor their health remotely while supplying healthcare professionals with reliable data to support diagnosis and treatment decisions. Certified as a Class IIa medical device in the EU, StethoMe bridges the gap between home care and professional medical support, improving patient outcomes and reducing healthcare system burdens[1][4][5].
Founded in 2015 in Poznan, Poland, StethoMe emerged from the need to address frequent respiratory illnesses in children and the broader challenge of remote respiratory monitoring. The founders, with backgrounds in healthcare and technology, developed the idea of combining a digital stethoscope with AI algorithms to analyze respiratory sounds remotely. Early pivotal moments included achieving CE certification as the first AI-based respiratory auscultation device and clinical validation protocols developed in collaboration with physicians and certification bodies, which helped build trust within the medical community[2][4].
StethoMe rides the growing trend of digital health and telemedicine, particularly accelerated by the COVID-19 pandemic, which highlighted the need for remote patient monitoring solutions. The timing is critical as healthcare systems worldwide seek to reduce in-person visits and manage respiratory diseases more effectively. Market forces such as increasing chronic respiratory conditions, rising healthcare costs, and patient demand for convenient care favor StethoMe’s adoption. By enabling professional-grade auscultation at home, StethoMe influences the ecosystem by advancing AI integration in medical devices and promoting patient-centered care models[4][5].
Looking ahead, StethoMe is poised to expand its impact by enhancing AI capabilities, broadening its user base beyond pediatrics to adult respiratory care, and integrating with broader telehealth platforms. Trends such as AI-driven diagnostics, personalized medicine, and remote healthcare delivery will shape its journey. Its influence may evolve from a niche respiratory monitoring tool to a core component of digital health ecosystems, potentially extending to other vital sign monitoring and chronic disease management. Continued regulatory approvals and clinical partnerships will be key to scaling its adoption globally[1][4][5].
StethoMe has raised $5.0M across 2 funding rounds. Most recently, it raised $3.0M Series A in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $3.0M Series A | TDJ Pitango Ventures | |
| May 1, 2017 | $2.0M Seed | TDJ Pitango Ventures |